Can 3D-CRT meet the desired dose distribution to target and OARs in glioblastoma? A tertiary cancer center experience

AIM: The purpose of the study is to perform a dosimetric analysis of the doses received by planning target volume and organ at risks in the postoperative glioblastoma by using 3D-conformal radiotherapy to a total dose of 60 Gy in 30 fractions. MATERIALS & METHODS: All patients received concurren...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Narendra, GY, Srinivasa, Dracham, Chinna B, Dey, Treshita, Madan, Renu, Khosla, Divya, Oinum, Arun, Kapoor, Rakesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546124/
https://www.ncbi.nlm.nih.gov/pubmed/32945180
http://dx.doi.org/10.2217/cns-2020-0010
_version_ 1783592167511425024
author Kumar, Narendra
GY, Srinivasa
Dracham, Chinna B
Dey, Treshita
Madan, Renu
Khosla, Divya
Oinum, Arun
Kapoor, Rakesh
author_facet Kumar, Narendra
GY, Srinivasa
Dracham, Chinna B
Dey, Treshita
Madan, Renu
Khosla, Divya
Oinum, Arun
Kapoor, Rakesh
author_sort Kumar, Narendra
collection PubMed
description AIM: The purpose of the study is to perform a dosimetric analysis of the doses received by planning target volume and organ at risks in the postoperative glioblastoma by using 3D-conformal radiotherapy to a total dose of 60 Gy in 30 fractions. MATERIALS & METHODS: All patients received concurrent temozolomide every day, and this was followed by adjuvant temozolomide of 5 days of treatment per month. RESULTS: More than 98% of patients were treated with a dose of 60 Gy. Doses were analyzed for the normal whole brain, tumor volume, as well as all the organs at risk. CONCLUSION: Given the grave prognosis and the limited survival of glioblastoma despite the best treatment available, makes 3D-conformal radiotherapy an equally acceptable treatment option.
format Online
Article
Text
id pubmed-7546124
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Future Medicine Ltd
record_format MEDLINE/PubMed
spelling pubmed-75461242020-10-16 Can 3D-CRT meet the desired dose distribution to target and OARs in glioblastoma? A tertiary cancer center experience Kumar, Narendra GY, Srinivasa Dracham, Chinna B Dey, Treshita Madan, Renu Khosla, Divya Oinum, Arun Kapoor, Rakesh CNS Oncol Research Article AIM: The purpose of the study is to perform a dosimetric analysis of the doses received by planning target volume and organ at risks in the postoperative glioblastoma by using 3D-conformal radiotherapy to a total dose of 60 Gy in 30 fractions. MATERIALS & METHODS: All patients received concurrent temozolomide every day, and this was followed by adjuvant temozolomide of 5 days of treatment per month. RESULTS: More than 98% of patients were treated with a dose of 60 Gy. Doses were analyzed for the normal whole brain, tumor volume, as well as all the organs at risk. CONCLUSION: Given the grave prognosis and the limited survival of glioblastoma despite the best treatment available, makes 3D-conformal radiotherapy an equally acceptable treatment option. Future Medicine Ltd 2020-09-18 /pmc/articles/PMC7546124/ /pubmed/32945180 http://dx.doi.org/10.2217/cns-2020-0010 Text en © 2020 Srinivasa GY This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License (http://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Research Article
Kumar, Narendra
GY, Srinivasa
Dracham, Chinna B
Dey, Treshita
Madan, Renu
Khosla, Divya
Oinum, Arun
Kapoor, Rakesh
Can 3D-CRT meet the desired dose distribution to target and OARs in glioblastoma? A tertiary cancer center experience
title Can 3D-CRT meet the desired dose distribution to target and OARs in glioblastoma? A tertiary cancer center experience
title_full Can 3D-CRT meet the desired dose distribution to target and OARs in glioblastoma? A tertiary cancer center experience
title_fullStr Can 3D-CRT meet the desired dose distribution to target and OARs in glioblastoma? A tertiary cancer center experience
title_full_unstemmed Can 3D-CRT meet the desired dose distribution to target and OARs in glioblastoma? A tertiary cancer center experience
title_short Can 3D-CRT meet the desired dose distribution to target and OARs in glioblastoma? A tertiary cancer center experience
title_sort can 3d-crt meet the desired dose distribution to target and oars in glioblastoma? a tertiary cancer center experience
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546124/
https://www.ncbi.nlm.nih.gov/pubmed/32945180
http://dx.doi.org/10.2217/cns-2020-0010
work_keys_str_mv AT kumarnarendra can3dcrtmeetthedesireddosedistributiontotargetandoarsinglioblastomaatertiarycancercenterexperience
AT gysrinivasa can3dcrtmeetthedesireddosedistributiontotargetandoarsinglioblastomaatertiarycancercenterexperience
AT drachamchinnab can3dcrtmeetthedesireddosedistributiontotargetandoarsinglioblastomaatertiarycancercenterexperience
AT deytreshita can3dcrtmeetthedesireddosedistributiontotargetandoarsinglioblastomaatertiarycancercenterexperience
AT madanrenu can3dcrtmeetthedesireddosedistributiontotargetandoarsinglioblastomaatertiarycancercenterexperience
AT khosladivya can3dcrtmeetthedesireddosedistributiontotargetandoarsinglioblastomaatertiarycancercenterexperience
AT oinumarun can3dcrtmeetthedesireddosedistributiontotargetandoarsinglioblastomaatertiarycancercenterexperience
AT kapoorrakesh can3dcrtmeetthedesireddosedistributiontotargetandoarsinglioblastomaatertiarycancercenterexperience

Ejemplares similares